Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

October 31, 2029

Conditions

Relapsed/Refractory Large B Cell Lymphoma

Interventions

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

GENETIC

ALLO-501A

ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

Trial Locations (2)

Universitair Ziekenhuis Brussel, Brussels

University of Louisville James Graham Brown Cancer Center, Louisville